Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alpine Immune Sciences Inc (NQ: ALPN )

8.520 +0.010 (+0.12%)
Streaming Delayed Price Updated: 10:12 AM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,013
Open 8.460
Bid (Size) 8.450 (2)
Ask (Size) 8.730 (3)
Prev. Close 8.510
Today's Range 8.460 - 8.530
52wk Range 6.000 - 14.40
Shares Outstanding 23,914,879
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Alpine Immune Sciences Appoints Andrew S. Sandler, M.D. as Chief Medical Officer
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Update on ALPN-303, a Dual BAFF/APRIL Inhibitor for Systemic Lupus Erythematosus and Other Autoimmune and Inflammatory Diseases, at EULAR 2022
From Alpine Immune Sciences Inc.
Via Business Wire

Performance

YTD
-38.66%
-38.66%
1 Month
-8.39%
-8.39%
3 Month
-5.02%
-5.02%
6 Month
-38.62%
-38.62%
1 Year
-5.33%
-5.33%

More News

Read More
The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More
Via Benzinga
Alpine Immune's Davoceticept Monotherapy Reduces Tumors In Early Stage Study
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Alpine Immune Sciences Announces Presentations at the 2022 EULAR and ASCO Annual Meetings
From Alpine Immune Sciences, Inc.
Via Business Wire
FDA Lifts Partial Hold On Alpine Immune's Davoceticept Combo Trial In Advanced Cancer
Via Benzinga
Alpine Immune Sciences Announces FDA Removes Partial Clinical Hold on NEON-2 Clinical Trial of Davoceticept (ALPN-202) in Combination with Pembrolizumab
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2022 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences Announces Participation in May Investor Conferences
From Alpine Immune Sciences, Inc.
Via Business Wire
AACR 2022: Davoceticept (ALPN-202) Monotherapy Reduces Tumors, Supports Multiple Expansion Cohorts
From Alpine Immune Sciences Inc.
Via Business Wire
The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More
Via Benzinga
The Week Ahead In Biotech (April 10-April 16): Regeneron FDA Decision, Cancer Conference Presentations And More
Via Benzinga
Alpine Immune Sciences Announces Company Presentation and Update on AACR Investor Event
From Alpine Immune Sciences Inc.
Via Business Wire
Alpine Immune Sciences Publishes Key Preclinical Rationale for Davoceticept (ALPN-202), a First-in-Class CD28 Costimulator and Dual Checkpoint Inhibitor, in Nature Communications
From Alpine Immune Sciences, Inc.
Via Business Wire
Alpine Immune Sciences to Host Virtual Investor Event at 2022 AACR Annual Meeting
From Alpine Immune Sciences, Inc.
Via Business Wire
58 Biggest Movers From Yesterday
Via Benzinga
38 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Alpine Immune Sciences Earnings Perspective: Return On Capital Employed
Via Benzinga
Alpine Immune Sciences Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
From Alpine Immune Sciences, Inc.
Via Business Wire
Why Alpine Immune's Shares Are Falling Today
Via Benzinga
Insider Buying Detected – Buy This Biotech Now
Via Talk Markets
73 Biggest Movers From Yesterday
Via Benzinga
50 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.